Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial NIH-NINDS U01 NS069498 An Overview of...
-
Upload
curtis-porter -
Category
Documents
-
view
212 -
download
0
Transcript of Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial NIH-NINDS U01 NS069498 An Overview of...
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
NIH-NINDS U01 NS069498
An Overview of SHINE
Contents
• Background• Trial Overview• Treatment Groups• Outcomes• I-SPOT Ancillary Study
SHINE Background
• Most animal stroke studies show that hyperglycemia at stroke onset leads to worse outcomes than normoglycemia:– Larger strokes – More brain edema – Greater hemorrhagic stroke transformation
J Cereb Blood Flow Metab 1997:17:553; Free Rad Biol Med 1997:23:986;
Stroke 1989;20:646
SHINE Background
• Most observational human studies reported independent associations between hyperglycemia (on admission as well as after hospitalization) and:– Greater infarct growth on MRI– Hemorrhagic stroke transformation when tPA used– Worse functional outcomes
Nat Rev Neurol 2010;6:145Lancet Neurol 2012;11:261
SHINE BackgroundHyperglycemia Impairs Thrombolysis/Recanalization
Nat Rev Neurol 2010;6:145
Acute & chronic hyperglycemia associated with impaired thrombolysis by enhancing thrombosis while inhibiting fibrinolysis
Ischemia with Ischemia withNormoglycemia Hyperglycemia
SHINE BackgroundHyperglycemia Impairs Tissue Reperfusion
Nat Rev Neurol 2010;6:145
Greater endothelial dysfunction leads to greater vasoconstriction even with recanalization
Ischemia with Ischemia withNormoglycemia Hyperglycemia
SHINE BackgroundHyperglycemia Increases Ischemic Tissue Damage
Nat Rev Neurol 2010;6:145
Greater oxidative stress, greater inflammatory response, greater acidosis, greater BBB leakage
Ischemia with Ischemia withNormoglycemia Hyperglycemia
SHINE BackgroundFavorable Outcome (mRS ≤1) at 3 months
Decreases as blood glucose increases
P=0.02 for all subjects
Neurology 2002;59:669
SHINE BackgroundSymptomatic ICH within 36 hrs of rt-PA
Increases as blood glucose increases
Neurology 2002;59:669
SHINE Background
• Greater tissue lactic acidosis• Increased local exitotoxic amino acids• Impaired recovery of elevated intracellular Ca2+
• Impaired cerebral vasoreactivity• Increased local free radicals• Increased blood-brain barrier leakage
Lancet Neurol 2012;11:261
Why might hyperglycemia during acute stroke be detrimental? Uncertain
SHINE Background
• Uncertainty whether the observed clinical associations are cause or effect or associated without causation– Is it the hyperglycemia makes strokes worse leading to worse
clinical outcomes or is it that more severe strokes and diabetes lead to worse clinical outcomes?
• Uncertainty when hyperglycemia is harmful:– during acute stroke with or without reperfusion?– with lacunar and non-lacunar strokes?
SHINE BackgroundEquipoise
• Will acute correction of hyperglycemia improve functional outcomes?
• Will patients without DM benefit from acute hyperglycemia correction?
• What is the treatment time window?• Is there a blood glucose threshold for favorable
outcome?• Will patients with lacunar strokes have better
outcomes with higher glucose?
SHINE Background1st Efficacy Trial: Glucose Insulin in Stroke Trial –
United Kingdom (GIST-UK)
• Stroke onset <24 hrs• 83% patients without DM• Relatively low blood glucose levels at baseline (~150
mg/dL)• Blood glucose in target range soon after treatment
started in both groups• Little separation of blood glucose levels between the 2
treatment groups (~10 mg/dL)• Trial stopped after only 40% of target enrolled; N=933• Primary outcome: death at 90 days
Lancet Neurol 2007;6:397
SHINE Background 1st Efficacy Trial: GIST-UK
Lancet Neurol 2007;6:397
SHINE Background 1st Efficacy Trial: GIST-UK
NSNS
Lancet Neurol 2007;6:397
SHINE BackgroundKey observations from 2 pilot NINDS clinical trials
• Hyperglycemia during acute stroke can be lowered in <6 hrs into target range with IV insulin protocols
• In patients without DM, hyperglycemia usually resolves rapidly without insulin treatment
• Hypoglycemia <60 mg/dL occurs in up to 40% of patients, but is usually asymptomatic
• Hypoglycemia occurs less frequently with computerized decision support tools
• Phase III trial warranted
Stroke 2008;39:384-9, Stroke 2009;40:3804-9
SHINE TrialNIH-NINDS U01 5NS069498
• Multicenter (~60 sites), randomized, controlled trial• Phase III (definitive efficacy trial)• Predominantly hyperglycemic acute ischemic stroke
patients• Comparison of standard SQ insulin vs IV insulin infusion• Funded by NIH-NINDS• Conducted in conjunction with NIH-NINDS funded
Neurological Emergencies Treatment Trials Network (NETT) and NIH-NINDS StrokeNet
In J Stroke 2014;9:246-51
SHINE TrialSpecific Aims
1. To determine the efficacy of tight glucose control to a range of 80-130 mg/dL with IV insulin infusion in hyperglycemic acute ischemic stroke patients w/in 12 hours of symptom onset as measured by mRS at 90 days.
2. To determine the safety of tight glucose control with IV insulin infusion in hyperglycemic acute ischemic stroke patients treated for up to 72 hrs as measured by rate of severe hypoglycemia (<40 mg/dL) in intervention group compared to the control group <4%.
SHINE TrialDesign Innovations
• Stratified randomization by IV tPA, stroke severity & site• Response-Adaptive Randomization – ↑ chance of
randomization to whichever group is doing better• Primary outcome: 90 day mRS – sliding dichotomy
• Total enrollment ~ 1400 subjects w/sample size re-estimation
• Futility and efficacy stopping boundaries• FDA cleared IV insulin decision support tool
Baseline NIHSS Favorable mRS outcome
3-7 08-14 0, 1
15-22 0, 1, 2
SHINE TrialDecision Support Tool - GlucoStabilizer®
• Designed at Indiana University/Clarian Health• Licensed by Medical Decision Network• FDA cleared and commercially available – used in
>65,000 patients• Considers individual patient response to insulin• Severe hypoglycemia rate (<40 mg/dL) - 1.67% of
patients and 0.07% of all glucose checks• Adherence to the recommendations – 99% – 91-98% in literature for decision support tools– 97% in GRASP
Crit Care Med 2008;36:1787-95, Stroke 2009;40:3804-9
SHINE TrialStatistical Power Estimations
• Favorable outcome rate in control group = 25% - based on pilot trials and relevant literature
• Favorable outcome in intervention group = 32% - judged to be the minimum clinically significant benefit (7% absolute difference)
• Estimated lost to follow-up = 3%• For an 80% power and a 2-sided type I error rate of
0.05 N=1400 (700/group)• Sample size re-estimation planned
SHINE Trial Eligibility – Inclusion Criteria
• Age ≥ 18 years• Diagnosis of acute ischemic stroke - neuroimaging
must exclude ICH• Type II DM & glucose >110 mg/dL OR no diabetes &
glucose ≥150 mg/dL • Baseline NIHSS 3-22 • Pre-stroke mRS of 0 if NIHSS 3-7; Pre-stroke mRS of
0-1 if NIHSS 8-22• Randomization w/in 12 hrs of stroke symptom onset• Valid informed consent
SHINE Trial Eligibility - Exclusion Criteria
• Type I DM • Condition confounding baseline neurological exam• Neurological or psychiatric illness likely to confound
primary outcome assessment at 90 days• Any experimental therapy for enrollment stroke – standard care IV tPA within 4.5 hrs, IA tPA & IA therapies w/
FDA cleared devices allowed. Non FDA cleared devices excluded
• Inability to follow the protocol or return for 90 day f/u• Serious conditions with unlikely 90 day survival• Pregnancy or breast-feeding• Any renal dialysis
SHINE TrialPre-stroke mRS Tips
SHINE Trial Baseline NIHSS & SHINE Eligibility
• NIHSS must be 3-22 and assessed ≤30 minutes prior to randomization
• Prior stroke deficits must not confound the acute stroke deficits
• Intubated patients are “untestable” for dysarthria and could be enrolled only if the NIHSS was scored before intubation and ≤30 minutes prior to randomization
SHINE Trial Qualifying Blood Glucose & SHINE Eligibility
• Must be done at the enrolling hospital• Must be a finger stick (capillary) blood • Consider rechecking if close to qualifying level and
time remains within the 12 hr window
SHINE TrialBlinding Strategy
• During acute treatment, single blind for patients/family
• All subjects receive study IV infusions and study SQ injections – some contain insulin & some contain saline placebo – only the clinical team members know which solutions contain insulin
• The primary & secondary outcomes are assessed by a blinded investigator resulting in a double blind outcome assessment
SHINE TrialTreatment Overview
• ~1400 hyperglycemic acute ischemic stroke patients• Single blind acute treatment; double blind final
outcome assessment
• 12 hr window from stroke symptom onset • Treatment Groups– Insulin drip 80-130 mg/dL – SQ insulin 80-179 mg/dL
• Up to 72 hrs treatment• Primary outcome - 90 day mRS - based on baseline
stroke severity strata
SHINE Treatment Groups General Concepts
• Two groups: both glucose control, both get insulin• All patients get IV drip & SQ injections (up to 4/day)• Frequent glucose checks to avoid hypoglycemia• All patients get 60 gram/meal carbohydrate diet• All patients must be in unit that supports IV insulin• Hypoglycemia prevention & management protocol
(Hold IV infusions & SQ injections for BG<80, give D50, check BG q15 min)
• 72 hr treatment period (early d/c OK)• Daily neuro & AE assessments• All sites provided with 1-2 study laptops
SHINE TrialControl Group
• Target glucose: 80-179 mg/dL• Glucose checks: q1-q3 hrs (+/- 15 min)• IV infusion: normal saline (placebo) – 4-5 cc/hr • SQ injections: human regular insulin per sliding scale,
given only @ 6:00, 12:00, 18:00, & 24:00• Escalating doses of insulin per sliding scale if not in
target, including a one-time dose of basal insulin @ 48 hrs in level 3
• Laptop displays SQ insulin sliding scale dosing and hypoglycemia protocol
SHINE Trial Static Control Treatment Screen
SHINE TrialControl Group Possible Level Advances
SHINE TrialIntervention Group
• Target glucose: 80-130 mg/dL• Glucose checks: q1-2 hrs (+/- 15 min) per
GlucoStabilizer®• IV infusion: human regular insulin – rate directed by
GlucoStabilizer® program based on glucose levels• SQ injections: – Normal saline (placebo) 0.05 cc @ 9:00 & 21:00 if NPO or on
continuous tube feeds OR– Rapid acting analog insulin after meals
SHINE TrialOutcomes
• Primary efficacy: baseline stroke severity adjusted 90 day mRS (sliding dichotomy)
• Secondary efficacy:– 90 day NIHSS– 90 day Barthel Index– 90 day SSQOL (Stroke Specific Quality of Life)
• Primary safety: severe hypoglycemia (BG<40mg/dL)
SHINE TrialCenters and Leadership
• Karen C. Johnston, MD, MSc (UVA) – Administrative PI• Askiel Bruno, MD, MS (GRU) – Protocol PI• Christiana Hall, MD, MS (UTSW) – Recruitment PI• William Barsan, MD (Univ of Michigan) NETT Clinical
Coordinating Center PI• Valerie Durkalski, PhD (MUSC) NETT Statistics and Data
Management Center PI
• Clinical enrolling sites: – NETT network – 22 hub/spoke complexes– StrokeNet sites to be included– 11 ancillary sites
SHINE TrialCenters
SHINE RecruitmentApril 2012 – July 2014
Age (mean yrs) 65Men (%) 56Race (%): White African American Asian Other
682723
Ethnicity (%): Non-Hispanic Hispanic Unspecified
84142
Symptom onset to randomized (median) 6 hrs 19 min
SHINE TrialData as of 6/3/2014 (N=381)
Baseline NIHSS (median)NIHSS strata (%) 3-7 8-14 15-22
8
483022
Qualifying POC glucose (mg/dL) 188
Pre-stroke diagnosed diabetes mellitus (%) 77
Lacunar stroke subtype (%) 23
IV tPA treated (%) 60
All IA treated (%) 11
SHINE TrialData as of 6/3/2014 (N=381)
SHINE TrialData as of 6/3/2014 (N=381)
Day 1 Day 2 Day 30
20
40
60
ICU Step-down Ward
Perc
ent
Hypoglycemia events: Subjects with any hypoglycemia (<70 mg/dL)(%) Subjects with any severe hypoglycemia (<40 mg/dL)(%) Subjects with neurological worsening for >24 hrs with
glucose ≤55 mg/dL (%) Subjects with seizure related to glucose <70 mg/dL (%)
302.10
0Mortality (%) 8.9
SHINE TrialData as of 6/3/2014 (N=381)
I-SPOT & SHINEInsights on Selected Procoagulation Markers and
Outcomes in Stroke Trial - 1U01 NS079077• I-SPOT seeks to determine if intense BG control
compared with standard BG treatment results in reductions in markers of blood coagulation
• Determine the relationships between blood glucose, markers of blood coagulation and thrombosis, and SHINE clinical outcomes
• Markers:– Whole blood Tissue Factor - PCA– Coagulation factors VII, VIIa, and VIII– Plasma TAT, Fragmin 1.2, D-dimer; – Tissue factor pathway inhibitor– Plasminogen activator inhibitor-1
I-SPOT & SHINEInsights on Selected Procoagulation Markers and
Outcomes in Stroke Trial – 1U01 NS079077• I-SPOT is a multi-center study nested within the
SHINE trial• A subset of 315 patients enrolled in the SHINE trial
will be enrolled in the I-SPOT study • Baseline & 48-hr blood samples collected, spun,
frozen, & batch sent to the main lab at Temple University
I-SPOT & SHINEInsights on Selected Procoagulation Markers and
Outcomes in Stroke Trial – 1U01 NS079077 Inclusion: • Must also be enrolled in the SHINE trialExclusions:• Thrombolytic treatments, e.g. IV or IA tPA• Full anticoagulation, e.g. heparin, warfarin, etc.• Moderate-severe hepatic insufficiency (INR>1.5, if
known, or history of variceal bleeding, or hepatic encephalopathy)
• History of thrombotic or hypercoagulable condition: e.g. antiphospholipid antibody syndrome, antithrombin III, Protein C or S deficiencies, congenital/Inherited factor deficiencies, sickle cell disease.
I-SPOT & SHINEInsights on Selected Procoagulation Markers and
Outcomes in Stroke Trial – 1U01 NS079077
• Allowed interventions– SQ DVT prophylactic anticoagulation doses– Standard antiplatelet treatments